Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients

作者：Besses Carlos^*; Alvarez Larran Alberto; Martinez Aviles Luz; Mojal Sergi; Longaron Raquel; Salar Antonio; Florensa Lourdes; Serrano Sergi; Bellosillo Beatriz

来源：British Journal of Haematology, 2011, 152(4): 413-419.

DOI：10.1111/j.1365-2141.2010.08467.x

• JAK2 V617F
• allele burden
• hydroxyurea
• polycythaemia vera
• essential thrombocythaemia

P>The modulation of JAK2 V617F allele burden dynamics was prospectively analysed in 47 patients (26 polycythaemia vera [PV] and 21 essential thrombocythaemia [ET]) treated with first-line hydroxyurea (HU) and compared with the JAK2 V617F dynamics of a control group of 45 PV and ET patients. A partial molecular response (PMR), according to European Leukaemia Net criteria, was observed in 27/47 (57%) patients. Median time to PMR was 14 months (3-66) with a probability of PMR at 3 years of 57%. A significant decrease in JAK2 V617F allele load was observed at 36 months both in PV and ET patients, being the reduction in PV higher than in ET patients (P = 0 center dot 01). A haematocrit >= 0 center dot 45 L/L was associated with a higher probability of attaining a PMR (HR:3 center dot 4; 95%CI:1 center dot 02-11 center dot 6, P = 0 center dot 04). Control group showed a slight increase of JAK2 V617F allele burden over time. The reduction in the mutated allele load comparing treated patients versus controls was highly significant both in PV and ET, demonstrating a clear effect of HU on the JAK2 V617F allele burden. In conclusion, first-line HU can attain PMR in more than 50% of newly diagnosed PV and ET patients, with a continuous decrease of the JAK2 V617F allele burden in PV patients during treatment.

• 出版日期2011-2